Results 181 to 190 of about 68,452 (304)

Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives. [PDF]

J Transl Med
Yang L, Zhang C, Zhang Z, Yao S, Shen J, Zhang Z, Xiao Z, Wang S, Wu Z.   +8 more
europepmc   +1 more source

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

Advanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong, Wenting Hui, Sai Qiao, Qifeng Ji, Miao Liu, Bangle Zhang, Daozhou Liu, Yumei Wu, Siyuan Zhou   +8 more
wiley   +1 more source

Organoid models for T cell-based immunotherapy in hepatobiliary cancers. [PDF]

Hepatobiliary Surg Nutr
Du L, Dong J, Du S.
europepmc   +1 more source

Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity

Advanced Science, EarlyView.
This study demonstrates that an albumin‐bound STING agonist (Nano ZSA‐51D) reprograms HSPCs to produce antitumor neutrophils with enhanced MHC I–mediated CD8+ T cell activation, thereby sensitizing tumors to α‐PD1 therapy. These findings highlight a strategy to target early hematopoiesis for shaping neutrophil fate and potentiating cancer immunotherapy.
Jinsong Tao, Hong‐Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Kai Sun, Wei Gao, Duxin Sun   +11 more
wiley   +1 more source

Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. [PDF]

Immunotherapy
Wang Y, Wu J, Huang X, Xiao Y.
europepmc   +1 more source

NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer

Advanced Science, EarlyView.
Multi‐omic profiling of T1 high‐grade bladder cancer identifies a high‐risk subtype (T1HG1) driven by NQO1, which couples anoikis resistance with immune evasion. NQO1 orchestrates macrophage–T cell crosstalk suppression via CXCL9 modulation. Pharmacological NQO1 inhibition with skullcapflavone II enhances cisplatin efficacy, representing a promising ...
Bin Guo, Chunru Xu, Shufan Fu, Qiang Cheng, Juan Li, Linkuo Shang, Gaojie Li, Yang Yang, Ying Wang, Yanqing Gong, Shengwei Xiong, Jian Fan, Changwei Yuan, Mei Zhang, Yifan Zuo, Elena Papaleo, Yue Shi, Yuan Liang, Xuesong Li, Hongzhao Li, Weimin Ci   +20 more
wiley   +1 more source

Does immunotherapy hold great promise in endometrial cancer care? [PDF]

Front Immunol
Braszka M, Chowaniec H, Borowczyk M, Dwojak E, Stępień M, Ślubowska A, Mielczarek M, Markiewicz H, Ałtyn R, Zieliński P, Czerniak J, Adamczak O, Kluk A, Dworacki G, Dobosz P.   +14 more
europepmc   +1 more source

Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy

Advanced Science, EarlyView.
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou, Yuting Li, Xudong Sun, Honghong Yang, Xiayu Shi, Lijia Yao, Jinhong Jiang, Erli Wang, Haoyang Wang, Yi Wei, Xiangsheng Liu   +10 more
wiley   +1 more source

Tumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression

Advanced Science, EarlyView.
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li, Lan Wang, Zihao Zhang, Chunmei Qian, Ning Li, Wei Huang, Qian Ba, Xiaojian Liu, Mayu Sun   +8 more
wiley   +1 more source

Immunotherapeutic Strategies for Prostate Cancer: A Comprehensive Review. [PDF]

Cancers (Basel)
Flores-Islas AK, Rico-Fuentes C, Sierra-Díaz E, García-Chagollán M, Pereira-Suárez AL, Zepeda-Nuño JS, Moreno-Ortiz JM, Ramírez-de-Arellano A.   +7 more
europepmc   +1 more source